title: Obstetric and offspring risks of women's morbid conditions linked to prior anticancer treatments.
abstract: BACKGROUND
  Literature shows the effects of type of cancer and/or anticancer treatment on live birth percentages and/or pregnancy and neonatal complications in female cancer survivors. However, studies analyzing the obstetric and offspring risks of the morbid conditions associated with previous anti-cancer treatments are missing. The present review aims to uncover these risks.
  
  
  METHODS
  A literature search based on publications up to March 2016 identified by PubMed and references cited in relevant articles.
  
  
  RESULTS
  The morbid conditions associated with prior anticancer treatments including chemotherapy, radiotherapy, surgery, and/or hematopoietic stem-cell transplant may induce not only obstetric and neonatal complications but also long-term effects on offspring. Whereas some risks are predominantly evidenced in untreated women others are observed in both treated and untreated women. These risks may be superimposed on those induced by the current women's trend in Western societies to postpone maternity.
  
  
  CONCLUSIONS
  Medical professionals should be aware and inform female cancer survivors wishing to have a child not only of the short- and long-term risks to themselves and their prospective offspring of previous anticancer treatments, fertility-preservation technologies, and pregnancy itself, but also of those risks linked to the morbid conditions induced by prior anticancer treatments. Once female cancer survivors wishing to have a child have been properly informed about the risks of reproduction, they will be best placed to make decisions of whether or not to have a biological or donor-conceived child. In addition, when medical professionals be aware of these risks, they will be also best placed to provide appropriate treatments before/during pregnancy in order to prevent or alleviate the impact of these morbid conditions on maternal and offspring health.
authors.affiliation: Department of Cellular Biology, Functional Biology and Physical Anthropology, Faculty of Biological Sciences, University of Valencia, Burjassot, Valencia, 46100, Spain. tarinjj@uv.es.
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Tarín
authors.affiliation: Department of Genetics, Faculty of Biological Sciences, University of Valencia, Burjassot, Valencia, 46100, Spain.|Research Unit-INCLIVA, Hospital Clínico de Valencia, Valencia, 46010, Spain.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: García-Pérez
authors.affiliation: Department of Pediatrics, Obstetrics and Gynecology, Faculty of Medicine, University of Valencia, Valencia, 46010, Spain.|Service of Obstetrics and Gynecology, University Clinic Hospital, Valencia, 46010, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Cano
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D036861:Delivery, Obstetric / Q000639:trends; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000639:trends; D006801:Humans; D009369:Neoplasms / Q000453:epidemiology* / Q000628:therapy*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects / Q000639:trends; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Fertility; Gestation; Gynecology; Pregnancy; Pregnancy complications